CJM-112

• Description :

  CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways[1].

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Smiles :

  [CJM-112]

• References & Citations :

  [1]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.|[2]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• Isoform :

  IL-17